Erratum

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36:2559–2565

Diabetes Care 2014;37:312 | DOI: 10.2337/dc14-er01b

In the print version of the article listed above, in Table 2, the units for stage II (12–24 weeks) ITCA 650 20→20 mg, ITCA 650 20→60 mg, and Ex-BID/ITCA 650 40 mg and for 0–24 weeks ITCA 650 20→60 mg should have been μg. In addition, the units in the sentences “In stage I (week 12), high anti-exenatide antibody titers were observed in 0, 2.1, and 4.5% of subjects treated with 20 and 40 mg/day of ITCA 650 and Ex-BID, respectively” and “In stage II (week 24), high titers were observed in 5.3, 7.0, 7.3, and 10% of subjects receiving 20, 40, 60, and 80 mg/day of ITCA 650, respectively” should have been μg/day. The online version reflects these changes.

Robert R. Henry, Julio Rosenstock, Douglas K. Logan, Thomas R. Alessi, Kenneth Luskey, and Michelle A. Baron